SCHEMBL24827544

SCHEMBL24827544

CCCC(C)(CC)C(=O)NCc1ncc(OC)c(=O)[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ POLB P06746 2/20 0.41
▸ RECQL P46063 1/20 0.34
▸ CDK4 P11802 1/20 0.33
▸ CCND1 P24385 1/20 0.33
▸ APLNR P35414 2/20 0.33
▸ GAA P10253 2/20 0.33
▸ LMNA P02545 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ TP53 P04637 1/20 0.30
▸ CYP3A4 P08684 1/20 0.30
▸ MAPT P10636 1/20 0.30
▸ ALOX15 P16050 1/20 0.30
▸ TSHR P16473 1/20 0.30
▸ ACAT1 P24752 1/20 0.30
▸ SOAT1 P35610 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20665413 0.84 ALDH1A1 (0.44) KDM4EALDH1A1POLBRECQLCDK4
SCHEMBL21776363 0.75 POLB (0.47) KDM4EALDH1A1POLBRECQLCDK4
SCHEMBL20665603 0.72 RECQL (0.46) KDM4EALDH1A1POLBRECQLCDK4
SCHEMBL23222270 0.70 KDM4E (0.51) KDM4EALDH1A1POLBRECQLCDK4
SCHEMBL24827537 0.68 ALDH1A1 (0.45) KDM4EALDH1A1POLBRECQLCDK4
SCHEMBL20417204 0.68 SMO (0.39) TDP1L3MBTL1
SCHEMBL20625836 0.68 AR (0.34) KDM4EAPLNRLMNAL3MBTL1TP53
SCHEMBL20625813 0.67 RIPK1 (0.33) —
SCHEMBL21900747 0.66 KDM4E (0.39) KDM4EALDH1A1POLBRECQLCDK4
SCHEMBL20665627 0.66 RECQL (0.49) KDM4EALDH1A1POLBRECQLCDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11541041-B1 Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease SHY Therapeutics LLC (US) 2023-01-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11541041-B1 Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease HRAS, KRAS, NRAS KDM4E 4215/4885ALDH1A1 3448/4885POLB 3534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback